Drug­mak­ers seek tweaks to FDA guid­ance on mea­sur­ing de­vel­op­ment in pe­di­atric tri­als

Bris­tol My­ers Squibb, No­var­tis, As­traZeneca and in­dus­try group BIO are all seek­ing al­ter­ations to the FDA’s re­cent draft guid­ance to help spon­sors mea­sure the growth …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER